Status:
UNKNOWN
Omics-based Predictors of NAFLD/Potential NASH
Lead Sponsor:
National Research Centre, Egypt
Conditions:
Non-Alcoholic Fatty Liver Disease
Non Alcoholic Steatohepatitis
Eligibility:
All Genders
12-60 years
Brief Summary
The cascade of care for the non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) requires crossing the barriers for their diagnosis and treatment. The ...
Detailed Description
The national treatment program intended to provide a cure for Egyptian HCV-infected patients was the sparking light toward an HCV-free and healthy liver among the Egyptian population. However, another...
Eligibility Criteria
Inclusion
- Age: 30-60 years for adults and 12-18 years for children
- BMI: ≥ 25 for adults, BMI: ≥ 85th and \<94th percentile for overweight and ≥95th percentile for obese children
- Pre-diabetics and type 2 diabetes
- Dyslipidemia
- Hypertension
- Family history of NASH
Exclusion
- • Alcohol consumption
- Type 1 diabetes
- Other chronic liver diseases
- Malignant diseases
Key Trial Info
Start Date :
August 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2024
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT05301231
Start Date
August 1 2022
End Date
April 30 2024
Last Update
June 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Research Centre
Giza, Giza Governorate, Egypt, 12411